Grass pollen allergoids - Allergopharma

Alternative Names: Allergovit 6 Grasses

Latest Information Update: 08 Nov 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Allergopharma
Class Allergens; Antiallergics; Plant allergy immunotherapies
Mechanism of Action Immunosuppressants; T lymphocyte modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Grass pollen hypersensitivity
Phase III Rhinoconjunctivitis; Seasonal allergic rhinitis

Most Recent Events

07 Aug 2017 Phase-II clinical trials in Rhinoconjunctivitis in Spain (SC) (EudraCT2017-000754-19)
07 Aug 2017 Phase-II clinical trials in Seasonal allergic rhinitis in Spain (SC) (EudraCT2017-000754-19)
19 Nov 2015 Phase-III clinical trials in Rhinoconjunctivitis (Prevention of relapse) in Germany (SC) (EudraCT2015-002409-13)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.